L3VLUP
ProSign in

BIO · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BIOVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BIO
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterBIOVRTX
Q3 202017 holders, $1.7bn31 holders, $21.9bn
Q4 202013 holders, $2.2bn30 holders, $18.4bn
Q1 202115 holders, $2.2bn31 holders, $15.4bn
Q2 202118 holders, $2.7bn30 holders, $12.7bn
Q3 202116 holders, $3.5bn35 holders, $10.1bn
Q4 202119 holders, $3.3bn28 holders, $12.4bn
Q1 202222 holders, $2.4bn23 holders, $16.1bn
Q2 202215 holders, $1.2bn25 holders, $18.1bn
Q3 202217 holders, $857m22 holders, $18.4bn
Q4 202216 holders, $782m28 holders, $18.4bn
Q1 202311 holders, $833m26 holders, $21.4bn
Q2 202316 holders, $607m27 holders, $24.7bn
Q3 202315 holders, $662m33 holders, $24.3bn
Q4 202311 holders, $534m32 holders, $28.6bn
Q1 20247 holders, $342m31 holders, $29.8bn
Q2 20246 holders, $409m29 holders, $33.4bn
Q3 20249 holders, $708m27 holders, $33.5bn
Q4 202411 holders, $649m26 holders, $28.5bn
Q1 202510 holders, $612m21 holders, $35.4bn
Q2 20258 holders, $780m21 holders, $32.3bn
Q3 20258 holders, $983m22 holders, $25.9bn
Q4 20259 holders, $1.2bn26 holders, $31.8bn
Q1 20268 holders, $1.2bn25 holders, $31.8bn
Q2 20267 holders, $1.1bn26 holders, $34.6bn
BIO

Bio Rad Labs Inc

Holders
7
Reported value
$1.1bn
Buyers
15
Sellers
13

Breadth +2 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$34.6bn
Buyers
21
Sellers
17

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BIO (4)

Caxton Associates LLP, First Eagle Investment Management LLC, Freestone Grove Partners LP, GAMCO Investors Inc

Only VRTX (23)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Bridgewater Associates LP, Citadel Advisors LLC, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Investments LP, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →